-
On-site negotiations on the adjustment of the national medical insurance drug list involve hundreds of clinical drugs
Time of Update: 2023-02-03
Since the establishment of the National Health Insurance Administration, the list of medical insurance drugs has been adjusted for four consecutive years, and a total of 507 new drugs and good drugs have been included and 391 drugs with uncertain efficacy have been transferred.
-
2023 Shenzhen Medical Fair
Time of Update: 2023-02-03
cn/shenzhen Address: Room 1003, Building A, Twin Buildings, No. 668 Xin Brick Road, Songjiang District, Shanghai Contact number: 18721265877 Contact WeChat: shenzhenexpo Contact person: Mr. Shen The 40th Shenzhen International Medical Equipment Exhibition 2023 will be held in Shenzhen World Exhibition and Convention Center on August 29-31, covering medical electronics and medical film Like equipment, intelligent medical care, ward nursing and auxiliary equipment, medical dressings, in vitro diagnostic reagents, optical first aid, rehabilitation nursing and medical informatization, etc.
-
In 2022, Mindray Medical Reception Institutions exceeded 5,000
Time of Update: 2023-02-03
According to the data, Mindray exceeded 270 blank customers in high-end hospitals and 350 horizontal customers in the first three quarters of 2022 in the life information and support production line.
-
Recently, medical companies have been taking frequent actions! Busy with acquisition, construction of R&D bases...
Time of Update: 2023-02-03
On January 4, 2023, it was learned that Canon Medical plans to spend US$300 million to open a new subsidiary, Canon Healthcare USA, in the United States, aiming to strengthen its imaging business and focus sales and investments on the US market.
-
Beijing adjusts the reimbursement standards for basic medical insurance medical materials All individual expenses below 1,000 yuan are included
Time of Update: 2023-02-03
According to the website of the Beijing Municipal Medical Security Bureau, the Beijing Municipal Medical Security Bureau recently issued a notice on adjusting the reimbursement standards for medical materials for basic medical insurance.
-
In 2022, there will be frequent personnel changes in pharmaceutical companies, with more than 250 senior executives leaving
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];The "big change" of management is a microcosm of the frequent changes in senior management in the pharmaceutical industry.
js?cdnversion='+~(-new Date()/36e5)];The "big change" of management is a microcosm of the frequent changes in senior management in the pharmaceutical industry.
-
The State Food and Drug Administration approved the marketing of 13 symptomatic treatment drugs for new coronavirus infection
Time of Update: 2023-02-03
Annex: List of varieties serial number Name of the drug specification dosage form Marketing Authorization Holder 1 Acetaminophen vitamin C effervescent tablets Each tablet contains 330 mg of paracetamol and 200 mg of vitamin C Tablets Hainan Taosheng Pharmaceutical Science and Technology Research Institute Co.
-
The scale of the domestic health industry has exceeded 13 trillion, and the equipment industry has attracted the attention of the industry!
Time of Update: 2023-02-03
(Image source: Pharma Network) It is understood that the industrial chain of the big health industry is very long, at present, China's health industry has formed a mature industrial system such as nutritional food, health food, health supplies, health care services, pharmaceutical industry, etc.
-
Review of the top 5 major events in the pharmaceutical industry in 2022
Time of Update: 2023-02-03
Dental implant collection landing On August 18, the National Health Insurance Administration issued the Notice on Carrying out Special Governance of Oral Implant Medical Service Charges and Consumables Prices (Draft for Comments), which mentioned the establishment of an interprovincial procurement alliance for dental implant consumables.
-
In 2023, the pharmaceutical industry after the change of senior management is worth waiting for!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Shortly after the beginning of 2023, the market reported that Hengrui Pharmaceutical, the "first brother of medicine", announced internally that Jiang Ningjun, who had been one of the founders of CStone Pharmaceutical, was appointed as the deputy general manager and chief strategy officer of Hengrui Pharmaceutical, and he was responsible for the company's clinical research and business development.
-
The development focus of traditional Chinese medicine innovative pharmaceutical enterprises, long-term opportunities are emerging
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Traditional Chinese medicine is one of the characteristics of Chinese medicine, in recent years, the approval speed of domestic innovative Chinese medicine drugs has increased significantly, and Chinese medicine innovative drugs and exclusive varieties have a greater competitive advantage in medical insurance procurement, in this context, some pharmaceutical companies have begun to take traditional Chinese medicine innovative drugs as the focus of the company's development.
-
In the first 11 months of 2022, the participation rate of basic medical insurance nationwide was stable at more than 95%.
Time of Update: 2023-02-02
The income of the basic medical insurance fund for urban and rural residents was 851.
The income of the basic medical insurance fund for urban and rural residents was 851.
The income of the basic medical insurance fund for urban and rural residents was 851.
-
The National Health Commission issued the 14th Five-Year Plan for Emergency Medical Rescue
Time of Update: 2023-02-02
Health commissions of all provinces, autonomous regions, municipalities directly under the Central Government and the Xinjiang Production and Construction Corps: In order to strengthen emergency medi
-
The construction of the standard system of pharmaceutical packaging materials in the Chinese Pharmacopoeia has entered an intensive publicity period, and the National Pharmacopoeia Commission has issued 3 more announcements!
Time of Update: 2023-02-02
cn Mailing address: Office of the National Pharmacopoeia Commission, Building 11, Fahua Nanli, Dongcheng District, Beijing Zip code: 100061 National Pharmacopoeia Commission 2023-01-04 identification QR code viewing attachment On January 4, the National Pharmacopoeia Commission announced the draft of two general standards for prefilled syringes, nine draft standards for general detection methods for prefilled syringes, and draft standards for the determination of insoluble particles in pharmaceutical packaging materials.
-
NMPA solicits opinions on the Measures for the Administration of Drug Standards, and Chinese Pharmacopoeia and drug standards are national standards!
Time of Update: 2023-02-02
Chapter III: Planning and Project Establishment Article 16 (Work Plan for National Drug Standards) The drug regulatory department under the State Council shall organize the National Pharmacopoeia Commission to formulate the outline for the preparation of the Chinese Pharmacopoeia, which shall be implemented after deliberation and approval by the plenary meeting of the Pharmacopoeia Committee.
-
Due to the failure to meet the expected data, some pharmaceutical companies announced the suspension of new drug research
Time of Update: 2023-02-02
js?cdnversion='+~(-new Date()/36e5)];Gene editing company Graphite Bio announced a voluntary moratorium on the phase 1/2 CEDAR study of nulabeglene autogedtemcel (nula-cell, GPH101) in sickle cell disease (SCD).
js?cdnversion='+~(-new Date()/36e5)];Gene editing company Graphite Bio announced a voluntary moratorium on the phase 1/2 CEDAR study of nulabeglene autogedtemcel (nula-cell, GPH101) in sickle cell disease (SCD).
-
Junshi PD-1 chases the deer in the Middle East! East China Pharmaceutical, Henlius, BeiGene...The "Belt and Road" market has become a blue ocean of innovative drugs in China?
Time of Update: 2023-02-02
On December 25, Junshi Biologics announced that it has reached a cooperation with Hikma MENA FZE (hereinafter referred to as "Hikma") for its PD-1 drug teripulimab. According to the announcement, Jun
-
CDE: Technical Guidelines for Immunogenicity Bridging Clinical Trials of Vaccines for Prevention (Draft for Comments) for comments
Time of Update: 2023-02-02
On December 21, the Center for Drug Evaluation of the State Food and Drug Administration publicly solicited comments on the "Technical Guidelines for Clinical Trials of Immunogenicity Bridging Clinical Trials of Preventive Vaccines (Draft for Comments)", and the time limit is one month from the date of issuance.
-
Straight to the point! On January 10, 5 listed companies were investigated by institutions, including two pharmaceutical companies
Time of Update: 2023-02-02
On January 10, Qianhong Pharmaceutical received a total of 8 institutional surveys, including three major securities companies such as Ping An Securities, Orient Securities and Everbright Securities, as well as Liuhe Investment and Huisheng Fund.
-
Pfizer P drug "soul bargain" negotiations failed! Azvudine in health insurance: let more patients use it
Time of Update: 2023-02-02
In 2021, the famous scene of "soul haggling" where 700,000 sky-high drugs were cut to more than 30,000 yuan is still fresh in memory. According to the concept of the Medical Insurance Bureau that "ev
